Business
Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program
Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program ...
About this update from Aurora Cannabis Inc.
[{"type":"text","content":"Aurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program\n\n\nAurora Cannabis Announces Filing of Prospectus Supplement for At-The-Market Offering Program\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntar{\nTEXT-ALIGN: RIGHT\n}\n\n\n\n\n\nPR Newswire\n\n\nNASDAQ | TSX: ACB\nEDMONTON, AB, Feb. 4, 2026 /PRNewswire/ - Aurora Cannabis Inc. (the \"Company\" or \"Aurora\") (NASDAQ: ACB) (TSX: ACB), the Canadian based leading global medical cannabis company, announced today that it has filed a prospectus supplement establishing a new at-the-market offering program (the \"ATM Program\") that allows the Company to issue and sell up to U.S.$100 million of common shares in the capital of the Company (the \"Common Shares\") from treasury to the public, from time to time, at the Company's discretion.\n\n\n\n\n\n\n\nThe Company intends to use the net proceeds from the Offering for strategic and accretive purposes only, including for increased cultivation capacity and M&A.\nAny Common Share sales under the ATM Program will be made through \"at-the-market distributions\" as defined in National Instrument 44-102 – Shelf Distributions and sold through the NASDAQ Capital Market (the \"NASDAQ\") or another marketplace in the United States at the prevailing market price at the time of sale. Sales may also be made in privately negotiated transactions. No sales will be made through a stock exchange or stock market in Canada.\nDistributions of the Common Shares through the ATM Program will be made pursuant to the terms of a sales agreement dated February 4, 2026 among the Company and TD Securities (USA) LLC.\nA prospectus supplement (the \"Prospectus Supplement\") to the Company's short form base shelf prospectus dated February 14, 2025 (the \"Base Shelf Prospectus\") has been filed with the securities commissions or securities regulatory authorities in each of the provinces of Canada, except Quebec, and with the U.S. Securities and Exchange Commission (the \"SEC\") as part of the Company's registration statement on Form F-10 (the \"Registration Sta...